These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 21545220)
1. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Huang S; Lin J; Guo N; Zhang M; Yun X; Liu S; Zhou J; He E; Skog S Asian Pac J Cancer Prev; 2011; 12(2):497-505. PubMed ID: 21545220 [TBL] [Abstract][Full Text] [Related]
2. Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Chen ZH; Huang SQ; Wang Y; Yang AZ; Wen J; Xu XH; Chen Y; Chen QB; Wang YH; He E; Zhou J; Skog S Sensors (Basel); 2011; 11(12):11064-80. PubMed ID: 22247653 [TBL] [Abstract][Full Text] [Related]
3. [Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors]. Cao X; Wang Y; Yang P; Zhou H; Liu C; Chen Z Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 39(10):1029-34. PubMed ID: 25355255 [TBL] [Abstract][Full Text] [Related]
4. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Chen Z; Zhou H; Li S; He E; Hu J; Zhou J; Skog S Anticancer Res; 2008; 28(6B):3897-907. PubMed ID: 19192647 [TBL] [Abstract][Full Text] [Related]
5. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker. Jagarlamudi KK; Hansson LO; Eriksson S BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026 [TBL] [Abstract][Full Text] [Related]
6. Serological TK1 predict pre-cancer in routine health screenings of 56,178 people. Wang Y; Jiang X; Wang S; Yu H; Zhang T; Xu S; Li W; He E; Skog S Cancer Biomark; 2018; 22(2):237-247. PubMed ID: 29689706 [TBL] [Abstract][Full Text] [Related]
7. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869 [TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Li HX; Lei DS; Wang XQ; Skog S; He Q Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816 [TBL] [Abstract][Full Text] [Related]
9. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Chen Y; Ying M; Chen Y; Hu M; Lin Y; Chen D; Li X; Zhang M; Yun X; Zhou J; He E; Skog S Int J Clin Oncol; 2010 Aug; 15(4):359-68. PubMed ID: 20354751 [TBL] [Abstract][Full Text] [Related]
10. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Zou L; Zhang PG; Zou S; Li Y; He Q Int J Biol Markers; 2002; 17(2):135-40. PubMed ID: 12113581 [TBL] [Abstract][Full Text] [Related]
11. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. Li Z; Wang Y; Ma J; He J; Zhou J; He E; Skog S Anticancer Res; 2010 Apr; 30(4):1295-9. PubMed ID: 20530443 [TBL] [Abstract][Full Text] [Related]
12. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Li Z; Wang Y; He J; Ma J; Zhao L; Chen H; Li N; Zhou J; He E; Skog S Eur J Cancer Prev; 2010 Jul; 19(4):313-8. PubMed ID: 20479645 [TBL] [Abstract][Full Text] [Related]
13. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Larsson AM; Bendahl PO; Aaltonen K; Jansson S; Forsare C; Bergqvist M; Jørgensen CLT; Rydén L Sci Rep; 2020 Mar; 10(1):4484. PubMed ID: 32161278 [TBL] [Abstract][Full Text] [Related]
14. Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people. Wang Y; Jiang X; Dong S; Shen J; Yu H; Zhou J; Li J; Ma H; He E; Skog S Cancer Biomark; 2016 Mar; 16(4):529-36. PubMed ID: 27002755 [TBL] [Abstract][Full Text] [Related]
15. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker. Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma. Boyé P; Floch F; Serres F; Geeraert K; Clerson P; Siomboing X; Bergqvist M; Sack G; Tierny D J Vet Intern Med; 2019 Jul; 33(4):1728-1739. PubMed ID: 31129922 [TBL] [Abstract][Full Text] [Related]
17. Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Xu XH; Zhang YM; Shu XH; Shan LH; Wang ZW; Zhou YL; Wen HK; He F; He E; Skog S Mol Med Rep; 2008; 1(5):705-11. PubMed ID: 21479474 [TBL] [Abstract][Full Text] [Related]
18. [Analysis of correlation between serum thymidine kinase 1 and acute myeloid leukemia]. Wang TJ; Sun AN; Wu DP; Li WY; Liang JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1095-8. PubMed ID: 24156413 [TBL] [Abstract][Full Text] [Related]
19. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519 [TBL] [Abstract][Full Text] [Related]